



UNIVERSITY OF LEEDS

This is a repository copy of *Response to Moldenhauer, Johnson & Van Mieghem ISPD 2022 DEBATE: There should be formal accreditation and ongoing quality assurance/review for units offering fetal therapy that includes public reporting of outcomes. MFAET, an international standardised medical terminology to support quality assurance/review for units offering fetal therapy.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/200030/>

Version: Accepted Version

Article:

David, AL and Spencer, RN orcid.org/0000-0002-3019-0322 (2023) Response to Moldenhauer, Johnson & Van Mieghem ISPD 2022 DEBATE: There should be formal accreditation and ongoing quality assurance/review for units offering fetal therapy that includes public reporting of outcomes. MFAET, an international standardised medical terminology to support quality assurance/review for units offering fetal therapy. *Prenatal Diagnosis*, 43 (4). pp. 563-564. ISSN 0197-3851

<https://doi.org/10.1002/pd.6335>

© 2023 John Wiley & Sons Ltd. This is the peer reviewed version of the following article: David, AL and Spencer, RN (2023) Response to Moldenhauer, Johnson & Van Mieghem ISPD 2022 DEBATE: There should be formal accreditation and ongoing quality assurance/review for units offering fetal therapy that includes public reporting of outcomes. MFAET, an international standardised medical terminology to support quality assurance/review for units offering fetal therapy. *Prenatal Diagnosis*, 43 (4). pp. 563-564. ISSN 0197-3851, which has been published in final form at

<https://doi.org/10.1002/pd.6335>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley's version of record on Wiley Online Library and any embedding, framing or

making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Response to Moldenhauer, Johnson & Van Mieghem ISPD 2022 DEBATE: There should be formal accreditation and ongoing quality assurance/review for units offering fetal therapy that includes public reporting of outcomes. MFAET, an international standardised medical terminology to support quality assurance/review for units offering fetal therapy

Dear Editor

In their debate on formal accreditation and ongoing quality assurance/review for units offering fetal therapy, authors Johnson, Moldenhauer and Van Mieghem highlight the importance of communicating outcomes and results to be able to compare centre performance. They point out that formal audit programs face considerable challenges not least that core outcome sets are only just becoming available for a few fetal conditions (1-3). Without objective measures of performance, however it is difficult for fetal therapy programs to assess their quality despite strong recommendations from international societies to do so voluntarily.

In 2021 we published MFAET, the first terminology to define maternal and fetal adverse events, and capture information on complications which can occur during fetal interventions (4). This system provides objective grading of a variety of fetal surgical complications including fetal operative injury, procedural and post-procedural haemorrhage, fetal bradycardia/tachycardia and fetal fluid collection. The terms have been mapped to MedDRA, the Medical Dictionary of Regulatory Activities. As an international standardised medical terminology it facilitates sharing of information between regulators, healthcare professionals, patients and research organisations.

Although designed as a tool for clinical trials, MFAET provides a standardised comprehensive assessment of medical occurrences in observational studies. Complications are graded 1-5 from mild with limited effect on the mother/fetus to grade 4 life-threatening and grade 5 indicating death. The system allows for the fact that some complications will have the potential to differentially affect the pregnant woman and the fetus, as some adverse events for example haemorrhage in pregnancy, preterm premature rupture of membranes and chorioamnionitis can be graded independently for the mother and fetus. Finally, the international consensus process that developed MFAET included patient input to ensure that it was relevant to all stakeholders of fetal therapy.

The adverse event terms added to MedDRA as part of MFAET development have already been used to systematically classify maternal and fetal intervention-related complications following open fetal myelomeningocele repair in a large Swiss prospective cohort (5). This allowed the team to assess their learning curve according to the complication rate and to observe for any correlation between life-threatening maternal and fetal complications.

While work is still ongoing to generate the necessary core outcome sets, we recommend to fetal therapy programs the opportunity to quality assess and benchmark their practice using the already developed MFAET system. Resources to support its use are available here (6) with options to recommend ways to improve the MFAET terminology system.

Yours sincerely

Anna David, Rebecca Spencer on behalf of the MFAET Steering Committee

References

1. Al Toukhi S, Whitehead CL, Ryan G, et al. Development of Core outcome set for fetal Myelomeningocele (COSMiC): study protocol. BMC Trials. 2020;21(1):732. <https://doi.org/10.1186/s13063-020-04668-6>
2. Vergote S, De Bie F, Bosteels J, et al. Study protocol: a core outcome set for prenatal interventions for congenital diaphragmatic hernia. Trials. 2021;22(1):158. <https://doi.org/10.1186/s13063-021-05120-z>
3. Perry H, Duffy JMN, Reed K, et al. Core outcome set for research studies evaluating treatments for twin-twin transfusion syndrome. Ultrasound Obstet Gynecol. 2019;54(2):255-261. <https://doi.org/10.1002/uog.20183>
4. Spencer R, Development of standard definitions and grading for Maternal and Fetal Adverse Event Terminology. Prenatal Diagnosis 2021
5. Vonzun L, Kahr MK, Noll F, Mazzone L, Moehrlen U, Meuli M, Heusler M, Krahenmann F, Zimmermann R, Ochsenbein-K€olble N. Systematic classification of maternal and fetal intervention-related complications following open fetal myelomeningocele repair – results from a large prospective cohort. BJOG 2020; <https://doi.org/10.1111/1471-0528.16593>.
6. <https://www.ucl.ac.uk/womens-health/how-can-i-use-maternal-fetal-adverse-event-terminology>